China's BGI Biotech Eyes 100 Million DNA Combos With Buy Of U.S. Firm
This article was originally published in PharmAsia News
Executive Summary
Beijing Genomics Institute, a start-up biotech in China, plans to use its $119 million acquisition of U.S.-based Complete Genomics to build a database of 100 million human DNA combinations.